Table 3.

Maximum grade of physician-reported lymphedema during the 24-month reporting period.

	Lymphedema Severity
	None	Grade 1	Grade 2	Grade 3	p-value (any)	p-value (grade 3+)
For all patients (N=321)	297 (92.5%)	20 (6.2%)	4 (1.3%)	0 (0%)
Vs treatment arm (N=321)
CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67)	56 (88.6%)	9 (13.4%)	2 (3.0%)	0 (0%)	0.007	NA
AC (Doxorubicin and Cyclophosphamide) (N=99)	95 (96.0%)	4 (4.0%)	0 (0%)	0 (0%)
Capecitabine (N=155)	146 (94.2%)	7 (4.5%)	2 (1.3%)	0 (0%)
Vs Most Extensive Surgery (N=319)
Breast Conserving Surgery (N=143)	134 (93.7%)	8 (5.6%)	1 (0.7%)	0 (0%)	0.453	NA
Full Mastectomy (N=176)	161 (91.5%)	12 (6.8%)	3 (1.7%)	0 (0%)
Vs Axillary Dissection (N=321)
No (N=65)	64 (98.5%)	1 (1.5%)	0 (0%)	0 (0%)	0.042	NA
Yes (N=256)	233 (91.0%)	19 (7.4%)	4 (1.6%)	0 (0%)
Vs Radiation Therapy (N=300)
No (N=139)	126 (90.7%)	11 (7.9%)	2 (1.4%)	0 (0%)	0.308	NA
Yes (N=161)	151 (93.8%)	9 (5.6%)	1 (0.6%)	0 (0%)
Vs Number of Nodes Examined (N=314)
0-3 (N=49)	47 (95.9%)	2 (4.1%)	0 (0%)	0 (0%)	0.023	NA
4-7 (N=58)	53 (100%)	0 (0%)	0 (0%)	0 (0%)
8+ (N=212)	190 (89.6%)	18 (8.5%)	4 (1.9%)	0 (0%)